The Clinical Application of Artificial Intelligence Assisted Renal Biopsy Diagnosis System.
1 other identifier
observational
2,900
1 country
2
Brief Summary
This research project aims to collect images from patients with chronic glomerulonephritis. For each subject, the images obtained from renal biopsy will undergo evaluation by both the diagnostic model and the 'gold standard' diagnosis by pathologists. The researchers will test the subjects using the diagnostic model and compare the results with the known 'gold standard' diagnosis, in order to evaluate the AUC, specificity, and sensitivity of the diagnostic model.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Jul 2024
Typical duration for all trials
2 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
July 1, 2024
CompletedFirst Submitted
Initial submission to the registry
December 28, 2025
CompletedFirst Posted
Study publicly available on registry
January 9, 2026
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 31, 2026
ExpectedStudy Completion
Last participant's last visit for all outcomes
December 31, 2026
January 27, 2026
December 1, 2025
2.5 years
December 28, 2025
January 25, 2026
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
The area under curve (AUC) of Receiver Operating Characteristic (ROC) curves of the TEM-AID artificial intelligence model
The area under curve (AUC) of Receiver Operating Characteristic (ROC) curves of the TEM-AID artificial intelligence model for candidates will be calculated.
baseline
Secondary Outcomes (2)
The specificity of the TEM-AID artificial intelligence model.
baseline
The sensitivity of the TEM-AID artificial intelligence model.
baseline
Eligibility Criteria
For patients with chronic kidney disease who need further diagnosis through renal biopsy.
You may qualify if:
- Voluntary signing of informed consent form;
- Patients clinically diagnosed or suspected of having chronic kidney disease according to the 2023 KDIGO Clinical Practice Guideline for the Evaluation and Management of Kidney Disease;
- Undergoing renal biopsy and pathological specimen preparation.
You may not qualify if:
- Biopsy tissue from donor kidney or transplanted kidney;
- Poor quality of pathological specimen, unable to conduct pathological diagnosis.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (2)
Nanfang Hospital
Guangzhou, Guangdong, China
Zhujiang Hospital of Southern Medical University
Guangzhou, Guangdong, China
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- OTHER
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
December 28, 2025
First Posted
January 9, 2026
Study Start
July 1, 2024
Primary Completion (Estimated)
December 31, 2026
Study Completion (Estimated)
December 31, 2026
Last Updated
January 27, 2026
Record last verified: 2025-12
Data Sharing
- IPD Sharing
- Will not share